Discovery of IRAK1/4/pan-FLT3 Kinase Inhibitors as Treatments for Acute Myeloid Leukemia

被引：1

作者：

Hoyt, Scott B. ^{[1
]}

Finocchio, Chris J. ^{[1
]}

Croll, Elizabeth ^{[1
]}

Tawa, Gregory J. ^{[1
]}

Li, Huixu ^{[2
]}

Ma, Li ^{[2
]}

Li, Kaikai ^{[2
]}

Liu, Li ^{[2
]}

Li, Ranran ^{[2
]}

Zhang, Xiaohu ^{[1
]}

Wilson, Kelli ^{[1
]}

Xu, Xin ^{[1
]}

Shah, Pranav ^{[1
]}

Williams, Jordan ^{[1
]}

Fang, Yuhong ^{[1
]}

Bolanos, Lyndsey C. ^{[3
]}

Gracia-Maldonado, Gabriel ^{[4
]}

Kolt, Amal ^{[4
]}

Robinson, Christina ^{[5
]}

Free, Jessica ^{[5
]}

Edmondson, Elijah F. ^{[5
]}

Difilippantonio, Simone ^{[5
]}

Jones, LaQuita M. ^{[6
]}

Culver-Cochran, Ashley E. ^{[3
]}

Rosenbaum, Jan S. ^{[4
]}

Starczynowski, Daniel T. ^{[3
]}

Thomas, Craig J. ^{[1
,7
]}

机构：

[1] Natl Ctr Adv Translat Sci, Rockville, MD 20850 USA

[2] WuXi AppTec Co Ltd, Tianjin 300457, Peoples R China

[3] Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol, Cincinnati, OH 45229 USA

[4] Kurome Therapeut, Cincinnati, OH 45208 USA

[5] Frederick Natl Lab Canc Res, Frederick, MD 21702 USA

[6] Cincinnati Childrens Hosp Med Ctr, Div Oncol, Cincinnati, OH 45229 USA

[7] NCI, Bethesda, MD 20814 USA

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2024年 / 15卷 / 11期

基金：

美国国家卫生研究院;

关键词：

IRAK1; IRAK4; FLT3; kinase; AML; leukemia;

D O I：

10.1021/acsmedchemlett.4c00269

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

We report the discovery of an imidazopyridine series of IRAK1/4/pan-FLT3 kinase inhibitors. Optimization of this series has produced compound 31 which displays potent and selective inhibition of IRAK1, IRAK4, FLT3, and all mutant forms of FLT3, as well as good in vitro ADME and pharmacokinetic properties. In a mouse xenograft model of AML, 31 produces survival prolongation equal to that of Gilteritinib, the leading marketed FLT3 inhibitor currently used to treat AML.

引用

页码：1843 / 1851

页数：9

共 50 条

[31] Developments and challenges of FLT3 inhibitors in acute myeloid leukemia
Ge, Shuai-Shuai
Liu, Song-Bai
Xue, Sheng-Li
FRONTIERS IN ONCOLOGY, 2022, 12
[32] Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia
Solana-Altabella, Antonio
Ballesta-Lopez, Octavio
Megias-Vericat, Juan Eduardo
Martinez-Cuadron, David
Montesinos, Pau
EXPERT OPINION ON EMERGING DRUGS, 2022, 27 (01) : 1 - 18
[33] Will FLT3 inhibitors fulfill their promise in acute myeloid leukemia?
Pratz, Keith W.
Luger, Selina M.
CURRENT OPINION IN HEMATOLOGY, 2014, 21 (02) : 72 - 78
[34] FLT3 Inhibitors in Acute Myeloid Leukemia: Increasing Options
Kadia, Tapan M.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (06) : 352 - 355
[35] FLT3 inhibitors in acute myeloid leukemia: Current and future
Thomas, Christan M.
Campbell, Peter
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (01) : 163 - 171
[36] FLT3 inhibitors: clinical potential in acute myeloid leukemia
Hospital, Marie-Anne
Green, Alexa S.
Maciel, Thiago T.
Moura, Ivan C.
Leung, Anskar Y.
Bouscary, Didier
Tamburini, Jerome
ONCOTARGETS AND THERAPY, 2017, 10 : 607 - 615
[37] Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments
Scholl, Sebastian
Fleischmann, Maximilian
Schnetzke, Ulf
Heidel, Florian H.
CELLS, 2020, 9 (11) : 1 - 18
[38] The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia
Fathi, Amir T.
Chen, Yi-Bin
EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 98 (04) : 330 - 336
[39] Efficacy of FMS-like Tyrosine Kinase 3 (FLT3) inhibitors in patients with acute myeloid leukemia
Htut, T. W.
Ball, S.
Khandelwal, N.
Wongsaengsak, S.
Mogollon-Duffo, F.
Jahan, N.
Quirch, M.
D'cunha, N.
Thein, K. Z.
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 52 - 53
[40] FLT3 and IRAK4 Inhibitor Emavusertib in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia
Seipel, Katja
Mandhair, Harpreet
Bacher, Ulrike
Pabst, Thomas
CURRENT ISSUES IN MOLECULAR BIOLOGY, 2024, 46 (04) : 2946 - 2960

← 1 2 3 4 5 →